In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|August 29, 2018
New EBSD Detector Features Advanced Sensors and Optics
Author(s)BioPharm International Editors
The Lumis electron backscatter diffraction (EBSD) detector incorporates a large-format complementary metal oxide semiconductor (CMOS) sensor to enable higher sample throughput, higher resolution measurements, and precise phase identification.
Advertisement
Thermo Fisher Scientific’s Lumis electron backscatter diffraction (EBSD) detector for electron microscopy is suited to help scientists, researchers, and engineers quickly and accurately identify new materials and understand how the structure of a material affects its properties.
The detector incorporates advanced optics with a new large-format complementary metal oxide semiconductor (CMOS) sensor that collects more than 2.2 megapixels to enable higher sample throughput, higher resolution measurements, and more precise phase identification. The CMOS sensor provides improved sensitivity at high frame rates due to a high dynamic range, increased quantum efficiency, and advanced noise management.
Scientists and researchers in metallurgy, geophysics, and other disciplines can use the Lumis EBSD detector to identify crystallographic phases and grain properties, as well as to monitor structural transformations in samples. The detector is also suited to help microscopists better understand failure mechanisms.
Additional benefits of the Lumis EBSD detector include:
- Compatibility with Thermo Scientific Pathfinder 2.0 microanalysis software, including new indexing algorithms
- High-speed data collection at several thousand frames per second
- Acquisition of patterns at probe currents below 10 pA for samples sensitive to microscope beam currents.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5